I have been an investor in CYDY for few years now. My

New Post Public Reply Private Reply Replies (0) Message Board
TechGuru
788
I have been an investor in CYDY for few years now. My perspective regarding time-frames have to be viewed as so. Have waited years for a moment like this so more months (if) are not something of concern to me. I perfectly understand others with shorter investment horizon and those that entered the fray at higher prices.

Having said that, now to the communication: the key here is the biostatistician’s opinion (we know we will no be stopped due to safety issues.). In order to eventually succeed we need to have good results in our interim . A bad ratio of deaths (LL/SOC) in this will produce a result that will mean that even continuing the trial with more patients will not produce a statistically-meaningful outcome. Or, put it in other words: LL helps somewhat but is not good enough to meet statistical significance. Or, put yet in another way: Leronlimab is not saving enough lives for the criteria normally used to approve.

A continuation of the trial means we are in our way to reach significance.

So, continuation of the trial is good news. Don’t take me wrong: of course, I would better have the trial ended right now (meaning the reduction of deaths, ROD henceforth, was in the order of 50%, p-value around 0.005). So, let’s assume this did not happen (don't know yet what will be communicated next Tuesday), let’s say we achieved ROD of 32.8% (the famous S. Hahn’s number that, implies a p-value of 0.068 close to statistical significance). This is an extremely good result !!! (we are saving 33 lives out of 100).

Yet, we might be requested to continue the trial as the power (with 195 patients) is not good enough (this is worse with a 2:1 allocation ratio requiring 12% more patients than a trial using 1:1 to detect the same size effect with equivalent power). All we have to do is to complete the trial and, hopefully, continue in the same trend of results.

Now, let’s assume our interim ROD was 20%, some would argue that this is still very good (we are saving lives !!), the problem here is that continuing the trial will unlikely result, at the end, in a p-value of <0.05.

Once again, continuation of the trial means it is understood that we got first-rate results and can meet the endpoints at the end. Clinical trials are difficult events (just check how many are successful overall). Being good does not mean one gets approved.

Another angle is the Severe/Critical split. The number of deaths stands at 23%. Most of them are coming from Critical patients, of course, as the overall patient averages are lower. What if the statistician determines that Leronlmab is extremely effective with the latter ??? The recommendation would be to continue with only Critical patients and/or increase the overall number to achieve a well-powered cohort for each group. Remember, we are running and adaptive trial.

Yet, there is also the secondary end-points which will add credence to the thesis of efficacy.

Please find below a table with the interim numbers and a scenario where in the second part of enrollment 30 patients die (due to better care as compared with first half) for a total of 75 deaths, and what it means at the end in respect to p-values and RODs. Right now (prior to interim) to "hit the ball out of the park" we need around 50%, at the end of the trial we will need around 33%. However, given the pandemic severity and the lack of alternatives I would not be surprised if even a ROD of 20%-25% is accepted and we get approval. I am using a two-binomial distribution test for the p-value calculations. The red lines are levels at which I recon we will be approved for interim and end of trial respectively.

Is a waiting game. Unfortunately we will not get any numbers, just opinions from the DSMB, mostly the biostatistician who will advise on what to do next.

And, we will depend on what CYDY wants to tell us as they do not have to give us the whole enchilada. Hopefully we will get it and some, however, bear in mind that there might not be enough data to keep us happy as the DSMB is obliged to recommend and not to report data.

1351144994_ScreenHunter_475Oct.1611.11.jpg

I remain very long and very optimistic about our prospects

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 253

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 112

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
UN Integrity Accelerator Targets Corporate Corruption

Updated Category News Views 10

Corruption rarely arrives wearing a villain costume; it shows up as a rushed payment, a friendly intermediary, or a contract nobody wants examined too closely. That is why the United Nations Global Compact's new Business Integrity Accelerator deserves a sober look. Launched November 18, 2026, the programme is not a magic shield, and nobody should sell it as one. But it...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 138

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 71

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 81

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 103

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming $100 into a Remarkable Asset with ISRG

Updated Category News Views 310

Investing in Intuitive Surgical: A Decade of Growth Investing in stocks can often lead to impressive returns, and when it comes to Intuitive Surgical (NASDAQ: ISRG), this statement holds particularly true over the past decade. With a remarkable annualized return of 24.63%, Intuitive Surgical has substantially outperformed the market, making it an attractive consideration...

Continue Reading
Giftify, Inc. Empowers Consumers Amid Increasing Food Costs

Updated Category News Views 181

How Giftify, Inc. is Supporting Consumers with Savings In a time where food prices are skyrocketing, especially in the grocery sector, Giftify, Inc. (NASDAQ: GIFT), the company behind the CardCash.com platform, is stepping up to support consumers. With rising egg prices and the increasing impact of inflation, Giftify is providing a practical solution for everyday...

Continue Reading
HCA Healthcare Posts Strong Results, Showcases Growth Potential

Updated Category News Views 315

HCA Healthcare Inc. Surpasses Expectations with Q3 Results HCA Healthcare Inc. (NYSE: HCA), recognized as one of the largest hospital operators in the country, recently shared its financial results for the third quarter of 2025. The company reported a notable increase in its financial metrics, showcasing resilience and growth amidst the evolving healthcare landscape....

Continue Reading
MedEx Ambulance Addresses Security Incident Resolution Steps

Updated Category News Views 379

Understanding the Recent Data Security Incident MedEx Ambulance, known for its dedication to emergency services, has recently faced a troubling data security incident. This incident has raised concerns about unauthorized access to both patient health records and employee personal details. Although operations have continued without disruption, MedEx feels it's crucial to...

Continue Reading
Blue Apron Tops Rankings for Home Meal Delivery Services

Updated Category News Views 139

Blue Apron Achieves Top Rank for Home Meal Delivery Blue Apron has risen to the highest rank for home-cooked meals through an extensive evaluation by Expert Consumers. This independent assessment focused on various meal delivery services, gauging them based on ingredient quality, recipe clarity, sourcing transparency, ease of use, and overall support for home cooking. Why...

Continue Reading